- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00544869
A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)
Phase 3 Open-label, Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure) - an Investigation of the Safety of Treatment Beyond 7 Days and the Effect of Dose Escalation to 30 mg
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Chubu region, Japan
-
Hokkaido region, Japan
-
Kanto region, Japan
-
Kinki region, Japan
-
Kyuush, Japan
-
Shikoku region, Japan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with cardiac edema receiving diuretic treatment since 7 days prior to the commencement of study drug administration.
Subjects receiving one of the following diuretic treatments since 3 days prior to the commencement of study drug administration without changing the dose or dosing regimen (including subjects scheduled to start treatment during the run-in observation period).
- 1. A loop diuretic at a daily dosage equivalent to 40 mg or more of furosemide
- 2. Concomitant administration of a loop diuretic and a thiazide diuretic (at any doses)
- 3. Concomitant administration of a loop diuretic and an anti-aldosterone drug (at any doses)
- CHF patients with lower limb edema, jugular venous distention, or pulmonary congestion due to extracellular volume expansion.
- Male or female subjects between the ages of 20 and 85, inclusive (at time of informed consent)
- Subjects able to stay at the study site from the day before the start of the run-in observation period until completion of post-treatment observation 2 (7 to 10 days after final study drug administration)
- Subjects capable of giving informed consent to participate in the study of their own free will
Exclusion Criteria:
- Heart failure patients with markedly fluctuating symptoms
- Patients with an assisted circulation device
Patients with any of the following complications or symptoms:
- 1. Suspected decrease in circulatory blood flow ,
- 2. Hypertrophic cardiomyopathy (other than dilated phase),
- 3. Cardiac valve disease with significant heart valve stenosis,
- 4. Hepatic coma
- Patients who develop acute myocardial infarction within 30 days prior to the screening examination
- Patients with a definite diagnosis of active myocarditis or amyloid cardiomyopathy
Subjects with any of the following complications or symptoms:
- 1. Poorly controlled diabetes melllitus,
- 2. Anuria,
- 3. Urination impaired due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
Subjects with any of the following disease histories:
- 1. Sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to the screening examination in subjects without an implanted defibrillator,
- 2. Cerebrovascular disorder within 6 months prior to the screening examination (other than asymptomatic cerebral infarction),
- 3. A history of hypersensitivity or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride.
- Subjects who are severely obese [body mass index (BMI, body weight (kg)/height (m)2] exceeding 35]
- Subjects with systolic blood pressure in the decubitus position exceeding 90 mmHg
Subjects with any of the following abnormal laboratory values:
- 1. Total bilirubin > 3.0 mg/dL,
- 2. serum creatinine > 3.0 mg/dL,
- 3. serum sodium > 147 mEq/L,
- 4. serum potassium > 5.5 mEq/L
- Patients who are unable to take oral medication
- Female subjects who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant during the study period
- Subjects who received any investigational drug other than OPC-41061 within 30 days prior to the screening examination
- Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
|
15-30mg/day,daily for 14days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body Weight
Time Frame: Baseline, Day 14 or at the time of final drug administration
|
The change of body weight from baseline at final observation
|
Baseline, Day 14 or at the time of final drug administration
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 156-06-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Edema
-
Otsuka Pharmaceutical Co., Ltd.RecruitingCardiac Edema (CHF)Japan
-
Otsuka Beijing Research InstituteCompleted
-
Taiwan Otsuka Pharm. Co., LtdCompletedCardiac-induced EdemaTaiwan
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Biobeat Technologies Ltd.CompletedAcute Cardiac Event | Acute Cardiac Failure | Acute Cardiac Pulmonary EdemaIsrael
-
Emergency Medical Service of the Central Bohemian...Masaryk Hospital Usti nad Labem; Institute of Experimental Physics, Slovak...Completed
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruiting
-
Indiana UniversityVanderbilt UniversityTerminatedHeart Failure | Acute Cardiac Failure | Acute Cardiac Pulmonary Edema | Heart Failure AcuteUnited States
-
Indiana UniversityWayne State University; Vanderbilt University; Case Western Reserve University; Inova Fairfax HospitalCompletedHeart Failure | Acute Cardiac Failure | Acute Cardiac Pulmonary Edema | Heart Failure AcuteUnited States
Clinical Trials on OPC-41061 (Tolvaptan)
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedHyponatremia | Inappropriate ADH Syndrome | Dilutional HyponatremiaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAutosomal Recessive Polycystic Kidney Disease (ARPKD)United States, Belgium, Spain, Germany, United Kingdom, Poland
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Development & Commercialization...CompletedChronic Kidney Disease | Autosomal Dominant Polycystic Kidney DiseaseAustralia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Co., Ltd.CompletedEdema | Heart Failure, CongestiveJapan
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.CompletedPolycystic Kidney Disease, Autosomal DominantUnited States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany